Literature DB >> 20628130

Long-term cause-specific mortality among survivors of childhood cancer.

Raoul C Reulen1, David L Winter, Clare Frobisher, Emma R Lancashire, Charles A Stiller, Meriel E Jenney, Roderick Skinner, Michael C Stevens, Michael M Hawkins.   

Abstract

CONTEXT: Survivors of childhood cancer are at increased risk of premature mortality compared with the general population, but little is known about the long-term risks of specific causes of death, particularly beyond 25 years from diagnosis at ages when background mortality in the general population starts to increase substantially.
OBJECTIVE: To investigate long-term cause-specific mortality among 5-year survivors of childhood cancer in a large-scale population-based cohort. DESIGN, SETTING, AND PATIENTS: British Childhood Cancer Survivor Study, a population-based cohort of 17,981 5-year survivors of childhood cancer diagnosed with cancer before age 15 years between 1940 and 1991 in Britain and followed up until the end of 2006. MAIN OUTCOME MEASURES: Cause-specific standardized mortality ratios (SMRs) and absolute excess risks (AERs).
RESULTS: Overall, 3049 deaths were observed, which was 11 times the number expected (SMR, 10.7; 95% confidence interval [CI], 10.3-11.1). The SMR declined with follow-up but was still 3-fold higher than expected (95% CI, 2.5-3.9) 45 years from diagnosis. The AER for deaths from recurrence declined from 97 extra deaths (95% CI, 92-101) per 10,000 person-years at 5 to 14 years from diagnosis, to 8 extra deaths (95% CI, 3-22) beyond 45 years from diagnosis. In contrast, during the same periods of follow-up, the AER for deaths from second primary cancers and circulatory causes increased from 8 extra deaths (95% CI, 7-10) and 2 extra deaths (95% CI, 2-3) to 58 extra deaths (95% CI, 38-90) and 29 extra deaths (95% CI, 16-56), respectively. Beyond 45 years from diagnosis, recurrence accounted for 7% of the excess number of deaths observed while second primary cancers and circulatory deaths together accounted for 77%.
CONCLUSION: Among a cohort of British survivors of childhood cancer, excess mortality from second primary cancers and circulatory diseases continued to occur beyond 25 years from diagnosis.

Entities:  

Mesh:

Year:  2010        PMID: 20628130     DOI: 10.1001/jama.2010.923

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  139 in total

1.  Aggregating traditional cardiovascular disease risk factors to assess the cardiometabolic health of childhood cancer survivors: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study.

Authors:  David C Landy; Tracie L Miller; Gabriela Lopez-Mitnik; Stuart R Lipsitz; Andrea S Hinkle; Louis S Constine; Carol A French; Amy M K Rovitelli; M Jacob Adams; Steven E Lipshultz
Journal:  Am Heart J       Date:  2012-02       Impact factor: 4.749

Review 2.  Collaborative Research in Childhood Cancer Survivorship: The Current Landscape.

Authors:  Smita Bhatia; Saro H Armenian; Gregory T Armstrong; Eline van Dulmen-den Broeder; Michael M Hawkins; Leontien C M Kremer; Claudia E Kuehni; Jørgen H Olsen; Leslie L Robison; Melissa M Hudson
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

Review 3.  Modulation of cardiovascular toxicity in Hodgkin lymphoma: potential role and mechanisms of aerobic training.

Authors:  Anthony F Yu; Lee W Jones
Journal:  Future Cardiol       Date:  2015-08-03

Review 4.  Second malignant neoplasms and cardiovascular disease following radiotherapy.

Authors:  Lois B Travis; Andrea K Ng; James M Allan; Ching-Hon Pui; Ann R Kennedy; X George Xu; James A Purdy; Kimberly Applegate; Joachim Yahalom; Louis S Constine; Ethel S Gilbert; John D Boice
Journal:  J Natl Cancer Inst       Date:  2012-02-06       Impact factor: 13.506

Review 5.  Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.

Authors:  Kirsten K Ness; Saro H Armenian; Nina Kadan-Lottick; James G Gurney
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

6.  Impact of treatment exposures on cardiovascular risk and insulin resistance in childhood cancer survivors.

Authors:  K Scott Baker; Eric J Chow; Pamela J Goodman; Wendy M Leisenring; Andrew C Dietz; Joanna L Perkins; Lisa Chow; Alan Sinaiko; Antoinette Moran; Anna Petryk; Julia Steinberger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-05       Impact factor: 4.254

7.  Limited evidence of non-response bias despite modest response rate in a nationwide survey of long-term cancer survivors-results from the NOR-CAYACS study.

Authors:  Hanne C Lie; Corina S Rueegg; Sophie D Fosså; Jon H Loge; Ellen Ruud; Cecilie E Kiserud
Journal:  J Cancer Surviv       Date:  2019-04-16       Impact factor: 4.442

Review 8.  Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology.

Authors:  Peggy M Kostakou; Nikos T Kouris; Vassilios S Kostopoulos; Dimitrios S Damaskos; Christoforos D Olympios
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

Review 9.  Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity.

Authors:  Nonniekaye Shelburne; Naoko I Simonds; Bishow Adhikari; Michael Alley; Patrice Desvigne-Nickens; Eileen Dimond; Kelly Filipski; Lisa Gallicchio; Lori Minasian
Journal:  Curr Oncol Rep       Date:  2019-01-30       Impact factor: 5.075

Review 10.  Cancer pharmacogenomics in children: research initiatives and progress to date.

Authors:  Shahrad Rod Rassekh; Colin J D Ross; Bruce C Carleton; Michael R Hayden
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.